Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib

Olga Mulas, Giovanni Caocci, Mario Annunziata, Bruno Martino, Luigiana Luciano, Fausto Castagnetti, Patrizia Pregno, Sara Galimberti, Francesco Albano, Ester M. Orlandi, Nicola Sgherza, Alessandra Iurlo, Massimiliano Bonifacio, Gianni Binotto, Antonella Gozzini, Monica Bocchia, Elisabetta Abruzzese, Claudio Fozza, Maria P. Simula, Fiorenza De GregorioGabriele Gugliotta, Francesca Pirillo, Claudia Baratè, Imma Attolico, Chiara Elena, Daniele Cattaneo, Luigi Scaffidi, Anna Sicuranza, Malgorzata M. Trawinska, Emilia Scalzulli, Robin Foà, Massimo Breccia, Giorgio La Nasa

Research output: Contribution to journalLetter

Original languageEnglish
JournalHematological Oncology
DOIs
Publication statusAccepted/In press - 2020

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Mulas, O., Caocci, G., Annunziata, M., Martino, B., Luciano, L., Castagnetti, F., Pregno, P., Galimberti, S., Albano, F., Orlandi, E. M., Sgherza, N., Iurlo, A., Bonifacio, M., Binotto, G., Gozzini, A., Bocchia, M., Abruzzese, E., Fozza, C., Simula, M. P., ... La Nasa, G. (Accepted/In press). Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib. Hematological Oncology. https://doi.org/10.1002/hon.2765